Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, China; Center of Clinical Epidemiology and Evidence-based Medicine, Fudan University, Shanghai, China.
Clin Immunol. 2023 Nov;256:109794. doi: 10.1016/j.clim.2023.109794. Epub 2023 Sep 27.
Takayasu arteritis (TAK) is complicated disorder without reliable biomarkers. Here, we aimed to explore TAK-associated factor panels and their changes after biologic treatment. Five factor panels were identified: 1. systemic inflammation: C3, ESR, CRP, PLT, IL-6, C4, and IgG; 2. vascular inflammation: YKL40, IL-16, PTX3, and CCL2; 3. immune regulation panel: IL-10, IFN-γ, CCL5, and MMP1; 4. angiogenesis and fibrosis: FGF, PDGFAB, and VEGF; and 5. vascular remodeling: CD19+ B cell ratio, MMP3, and leptin. Panel 1 parameters were closely related to disease activity, while Panel 5 parameters, particularly CD19+ B cell ratio and leptin, were significantly higher in ischemic patients. After treatment, tocilizumab had a stronger inhibitory effect on Panel 1 parameters, PTX3, and YKL-40, while adalimumab led to an increase in IL-16, CCL2, and leptin levels. Altogether, these data expanded our knowledge regarding molecular background in TAK development and shed light on precise treatment in future studies.
Takayasu 动脉炎（TAK）是一种复杂的疾病，没有可靠的生物标志物。在这里，我们旨在探讨 TAK 相关的因子谱及其在生物治疗后的变化。确定了五个因子谱：1. 全身炎症：C3、ESR、CRP、PLT、IL-6、C4 和 IgG；2. 血管炎症：YKL40、IL-16、PTX3 和 CCL2；3. 免疫调节谱：IL-10、IFN-γ、CCL5 和 MMP1；4. 血管生成和纤维化：FGF、PDGFAB 和 VEGF；5. 血管重塑：CD19+B 细胞比、MMP3 和瘦素。第 1 组参数与疾病活动密切相关，而第 5 组参数，特别是 CD19+B 细胞比和瘦素，在缺血患者中明显升高。治疗后，托珠单抗对第 1 组参数、PTX3 和 YKL-40 有更强的抑制作用，而阿达木单抗导致 IL-16、CCL2 和瘦素水平升高。总的来说，这些数据扩展了我们对 TAK 发展分子背景的认识，并为未来的研究提供了精确治疗的启示。
